Schütz Florian
Universitätsfrauenklinik Heidelberg, Germany.
Breast Care (Basel). 2008;3(4):257-261. doi: 10.1159/000149816. Epub 2008 Aug 20.
Every oncologist has a dream - doing more with less toxicity. Targeted therapies seem to be the key for an oncologist's dreams by defining subgroups of those patients who benefit more from a specific treatment and those who do not. For a few years now, targeted therapies have played a major role in the treatment of primary as well as metastatic breast cancer. In this article, we describe targeted therapies that already play an important role in clinical decisions in the treatment of metastatic as well as primary breast cancer. The humanised monoclonal antibody trastuzumab is a very effective agent in primary and metastatic breast cancer, but only for those patients whose tumours are overexpressing HER2/neu. Bevacizumab is an antibody directed against vascular epidermal growth factor ligand A which plays a role in angiogenesis. Up to now there is no predictive factor known for this treatment. Furthermore, we would like to give an impression of new agents and strategies under investigation like tyrosine kinase inhibitors and other small molecules.
每位肿瘤学家都有一个梦想——用更低的毒性实现更好的治疗效果。靶向治疗似乎是实现肿瘤学家梦想的关键，它通过界定哪些患者亚组能从特定治疗中获益更多，哪些则不能。几年来，靶向治疗在原发性及转移性乳腺癌的治疗中发挥了重要作用。在本文中，我们描述了在转移性及原发性乳腺癌治疗的临床决策中已发挥重要作用的靶向治疗。人源化单克隆抗体曲妥珠单抗在原发性和转移性乳腺癌中是一种非常有效的药物，但仅适用于那些肿瘤过度表达HER2/neu的患者。贝伐单抗是一种针对血管内皮生长因子配体A的抗体，其在血管生成中起作用。到目前为止，尚无已知的该治疗的预测因子。此外，我们还想介绍一些正在研究的新药物和策略，如酪氨酸激酶抑制剂及其他小分子药物。
